Author/Editor		Hochmair, Maximilian J; Morabito, Alessandro; Hao, Desiree; Yang, Cheng-Ta; Soo, Ross A; Yang, James C-H; Gucalp, Rasim; Halmos, Balazs; Wang, Lara; Golembesky, Amanda; Märten, Angela; Čufer, Tanja
Title		Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
Type		članek
Vol. and No.		Letnik 14, št. 27
Publication year		2018
Volume		str. 2861-2874
ISSN		1744-8301 - Future oncology (London, England)
Language		eng
Abstract		Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials & methods: In this retrospective, observational, multicenter study, patients (n = 204) had T790M-positive disease following first-line afatinib and started osimertinib treatment [>/=]10 months prior to data entry. Primary outcome was time on treatment. Results: Overall median time on treatment was 27.6 months (90% CI: 25.9-31.3), 30.3 months (90% CI: 27.6-44.5) in Del19-positive patients and 46.7 months (90% CI: 26.8-not reached) in Asians. The 2-year overall survival was 78.9%. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib facilitates prolonged, chemotherapy-free treatment in patients with T790M acquired resistance, and is a potentially attractive strategy, especially for Del19-positive tumors.
Descriptors		Lung neoplasms Pljučne novotvorbe Therapy Terapija
Keywords		non-small-cell lung cancer afatinib osimertinib epidermal growth factor receptor EGFR observational study nedrobnocelični pljučni rak afatinib osimertinib receptor za epidermalni rastni dejavnik EGFR opazovalna raziskava